received honoraria as a speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elpen, Galenica, GSK, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Takeda and Vianex
The critical insight: stopping early often leads to weight regain, while staying consistent produces durable metabolic improvements including better insulin sensitivity and reduced cardiovascular risk markers
Begin semaglutide at 0.25 mg weekly (Ozempic titration schedule) or at whatever dose is appropriate for the patient's history
Retrieved from Rodbard, H
During this period, you should also commit to building healthy eating habits you can maintain long after treatment ends
Our study detected a robust genetic association with GLP1 medication weight loss efficacy and associated side effects